The Chairman of the Board of Directors at Aptahem has announced his resignation
Aptahem AB (publ), announce today that the Chairman of the Board of Directors, Kjell G Stenberg, has requested his own resignation from the Board. Due to this, the Board of Directors will call for an Extraordinary General Meeting to elect a new chairman. Until then, the Board has appointed the current Board Member Theresa Comiskey Olsen as interim Chairman.
For further information:
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
This information is information that Aptahem AB is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the contact persons above, for publication on 3 September 2020.
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.